TOKENPOST
1 min read
Add as a preferred source on Google

Geron Plans to Discontinue Late-Stage Rytelo Trial After Efficacy Concerns

Geron shares fell more than 20% Wednesday as the company moved to end the study.

By John Kim
Published
An unmarked vial beside an empty specimen rack in a lab / TokenPost.ai
An unmarked vial beside an empty specimen rack in a lab / TokenPost.ai

The planned discontinuation applies to a late-stage study of imetelstat, Geron’s lead asset, which the company markets as Rytelo. The move followed concerns about the drug’s efficacy. Geron shares fell more than 20% Wednesday, Oct. 28.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…